SpyGlass Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	26.82	12.27	7.08
Research & Development	35.28	29.18	19.98
Operating Expenses	62.11	41.45	27.06
Operating Income	-62.11	-41.45	-27.06
Interest & Investment Income	6.05	3.11	1.32
Other Non Operating Income (Expenses)	-	-1.53	-3.42
Pretax Income	-56.05	-39.87	-29.16
Net Income	-56.05	-39.87	-29.16
Net Income to Common	-56.05	-39.87	-29.16
Net Income Growth	-	-	-
Shares Outstanding (Basic)	14	2	2
Shares Outstanding (Diluted)	14	2	2
Shares Change	-	23.98%	-
EPS (Basic)	-3.88	-17.98	-16.31
EPS (Diluted)	-3.88	-17.98	-16.31
EPS Growth	-	-	-
Free Cash Flow	-49.74	-33.49	-24.02
Free Cash Flow Per Share	-3.44	-15.11	-13.43
EBITDA	-61.09	-40.84	-26.79
D&A For EBITDA	1.01	0.61	0.27
EBIT	-62.11	-41.45	-27.06

SEC Filings: 10-K · 10-Q